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The proto-oncogene proviral integration site for moloney murine leukemia virus (PIM) kinases (PIM-1, PIM-2, and
PIM-3) are serine/threonine kinases that are involved in a number of signaling pathways important to cancer cells.
PIM kinases act in downstream effector functions as inhibitors of apoptosis and as positive regulators of G1-S
phase progression through the cell cycle. PIM kinases are upregulated in multiple cancer indications, including
lymphoma, leukemia, multiple myeloma, and prostate, gastric, and head and neck cancers. Overexpression of one
or more PIM family members in patient tumors frequently correlates with poor prognosis. The aim of this
investigation was to evaluate PIM expression in low- and high-grade urothelial carcinoma and to assess the role
PIM function in disease progression and their potential to serve as molecular targets for therapy. One hundred
thirty-seven cases of urothelial carcinoma were included in this study of surgical biopsy and resection specimens.
High levels of expression of all three PIM family members were observed in both noninvasive and invasive
urothelial carcinomas. The second-generation PIM inhibitor, TP-3654, displays submicromolar activity in
pharmacodynamic biomarker modulation, cell proliferation studies, and colony formation assays using the UM-
UC-3 bladder cancer cell line. TP-3654 displays favorable human ether-à-go-go-related gene and cytochrome P450
inhibition profiles compared with the first-generation PIM inhibitor, SGI-1776, and exhibits oral bioavailability.
In vivo xenograft studies using a bladder cancer cell line show that PIM kinase inhibition can reduce tumor growth,
suggesting that PIM kinase inhibitors may be active in human urothelial carcinomas.
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The serine/threonine family of proviral integration site for moloney
murine leukemia virus (PIM) kinases was first identified as proto-
oncogenes activated in T cell lymphomas induced by murine
leukemia viruses. The PIM kinase family comprises three members
(PIM-1, PIM-2, and PIM-3) with six different isoforms from
alternate translation-initiating sites [1–5]. Although the PIM kinase
family is transcriptionally and translationally regulated in cells, these
kinases lack a regulatory domain and are constitutively activated when
expressed [6–10].
Expression of PIM-1 is induced by several cytokines, which often
activate signal transducer and activator of transcription 5 (STAT5) in
conjunction with PIM-1. In fact, the PIM kinases are target genes
of STAT3 and STAT5 signaling and are correlated with levels
of STAT signaling [11–15]. They often form complexes with heat
shock protein 70 and Hsp90 for stabilization but are eventually
polyubiquitinated for proteasomal degradation [11–15].
Although they are frequently implicated in acute myeloid leukemia
(AML) [16], PIM kinases are overexpressed in many other types of
hematological malignancies and solid tumors. Specifically, overexpres-
sion has been identified in bladder [17], prostate [18], and head and
neck cancers [19] and chronic lymphocytic leukemia [20], multiple
myeloma [21], and other B cell malignancies [22]. Overexpression of
PIM kinases is often associated with poor prognosis in each of these
cancers. For example, prostate tumors expressing high levels of PIM
exhibited higher Gleason scores and differentiation [23]. Expression of
Pim-1 has also been shown to predict poor prognosis in esophageal
carcinoma [24] and gastric cancer [25].
The PIM kinases have a variety of downstream targets that are thought
to contribute to tumor growth. In particular, PIM kinases target the
proapoptotic B cell lymphoma 2–associated death promoter (BAD)
family members and inhibit apoptosis [6–10]. Inhibition of PIM kinases
has also been shown to decrease eukaryotic translation initiation factor 4E
binding protein 1 (4EBP1) and cyclin D1 protein levels, suggesting a role
for PIM kinases in translation and cell cycle regulation [26].
In addition to their role in apoptosis, PIM kinases have been shown
to contribute to activation of oncogenic MYC signaling. PIM-1
phosphorylates serine 10 of histone H3 on the nucleosome of c-myc–
binding sites, and this colocalization contributes to increased
transcriptional activation of c-myc [27]. It has also been shown that
overexpression of PIM-1 or PIM-2 stabilizes c-MYC by phosphor-
ylation on Ser239 [28]. An ex vivo analysis of human prostate tumors
showed that coexpression of PIM-1 and c-MYC is associated with
higher Gleason scores [29]. PIM kinases are attractive therapeutic
targets because of their clear role in inhibition of apoptosis,
promotion of cell proliferation, and interactions with c-MYC [30].
Crystal structures of the PIM kinases have been used to understand
their unique ATP binding pocket and for computational and
medicinal chemistry efforts to develop inhibitors. The hinge region
of PIM kinases is unusual in that it contains a proline residue not
generally present in serine/threonine kinase hinges, as well as other
unique residues in the ATP binding cleft [27,28,31–34]. Astex
Pharmaceuticals, Inc (formerly SuperGen, Inc) (Salt Lake City, UT)
developed an imidazopyridazine-based inhibitor, SGI-1776, that
exhibited potent anti-PIM activity both in vitro and in vivo in a
variety of preclinical models [35–38]. Studies have demonstrated that
SGI-1776 exhibited potent antitumor activity in preclinical models of
fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)
mutant AML [38–40]. Investigators have demonstrated that theobserved activity in this model system may be due to the predominant
anti-FLT3 activity [41]. In contrast, models without the FLT3-
internal tandem duplication (ITD) mutation were sensitive to SGI-
1776, suggesting that PIM-specific activity may be responsible for the
observed antiproliferative effects [42–47]. Ultimately, SGI-1776 was
evaluated in a phase I clinical trial recruiting patients with either
castration-resistant prostate cancer or relapsed/refractory non-Hodg-
kin lymphoma. However, the trial was terminated early due to a
narrow therapeutic window, which resulted in cardiac QT
prolongation. The cardiotoxicity has since been attributed to
inhibition of the cardiac potassium channel human ether-à-go-go-
related gene (hERG), also observed with SGI-1776 and related
metabolites in functional assays.
Our recent efforts focused on identifying a novel PIM kinase
inhibitor with a unique antikinase profile and attractive pharmaceutical
properties. In this report, we describe the discovery and characterization
of a second-generation small-molecule PIM kinase inhibitor, TP-3654
(SGI-9481), which exhibits potent activity against all three PIM kinases
but with reduced activity against FLT3 and hERG.
The design of TP-3654 began with the virtual screening of a large
number of library compounds, which identified pyrazolo[1,5-a]pyrim-
idines as active scaffolds against the PIM kinases. The pyrazolo[1,5-a]
pyrimidine chemotype was of particular interest as the core structure was
different from the imidazo[1,2- b]pyridazine compounds (SGI-1776),
which were identified as selective and potent PIM inhibitors but with
significant hERG and cytochrome P450 inhibition. Starting from this
initial hit compound and SGI-1776, we combined the pyrazolo[1,5-a]
pyrimidine core with the substituents at the 3,5-positions of SGI-1776
and generated a lead compound, which had an inhibition concentration
50% (IC50) = 45 nM for PIM-1 kinase. On the basis of the structure of
this lead compound, we conducted systematic modifications around
this scaffold to improve in vitro potency against the PIM kinases, as well
as other critical physicochemical properties. TP-3654 retains potent
pan-PIM inhibition but with minimal to no hERG and cytochrome
P450 inhibition as observed with SGI-1776.
PIM-1 has been observed in invasive and noninvasive urothelial
carcinoma specimens, with a higher incidence in invasive cancer [17].
However, because the role of PIM kinases in bladder cancer is not
well characterized, we sought to further evaluate PIM expression in
low- and high-grade urothelial carcinoma. One hundred thirty-seven
cases of urothelial carcinoma were included in this study of surgical
biopsy and resection specimens. Furthermore, we evaluated the
activity of TP-3654 in bladder cancer cell lines in vitro and in human
xenograft mouse models. Overall, the data presented here provide
preclinical activity to support the potential application of this
inhibitor in urothelial carcinomas.
Materials and Methods
Synthesis of TP-3654
TP-3654 {4-((3-(3-(Trifluoromethyl)phenyl)imidazo[1,2-b]pyri-
dazin-6-yl)amino) -trans-cyclohexyl)propan-2-ol} was prepared ac-
cording to US Patent Application Publication US2012/0058997
(Imidazo[1,2-b]pyridazine and pyrazolo[1,5-A]pyrimidine derivatives
and their use as protein kinase inhibitors).
PIM Kinase IC50 and Ki Determinations
PIM kinase Ki determinations, TP-3654 selectivity screens, and
IC50 determinations were performed by Reaction Biology (Malvern,
Neoplasia Vol. 16, No. 5, 2014 PIM kinases: a target for urothelial carcinoma Foulks et al. 405PA). For Ki determination, PIM-1, PIM-2, or PIM-3 were incubated
with 10-dose, three-fold serial dilutions of TP-3654 starting with
10 μM using five different concentrations of ATP (25, 50, 100, 250,
and 500 μM ATP for PIM-1; 5, 10, 20, 50, and 100 μM ATP for
PIM-2 and PIM-3), and the activity was measured at 0, 5, 10, 15, 20,
30, 45, 60, 75, 90, 105, and 120 minutes. The data were analyzed in
a Michaelis-Menten plot to determine apparent Km and Ki values
using GraFit software (Erithacus Software, London, UK) using a
mixed inhibition equation for global fit. For selectivity, 1 μM TP-
3654 was tested against 336 kinases at a concentration of 10 μM
ATP. IC50 determinations of phosphoinositide 3-kinase (PI3K) (α, β,
δ, and γ) and all kinases inhibited by N50% from the initial screen
were performed using 10-dose, three-fold serial dilutions of TP-3654
starting with 10 μM at Km ATP concentrations for each kinase.Cell Lines
The T24, RT4, J82, and UM-UC-3 bladder cancer cell lines were
obtained directly from the American Type Culture Collection (ATCC)
in Manassas, VA. These cell lines were passaged for less than 6 months
before used in the described assays and were authenticated by ATCC.
The MV4-11, PC-3, HEK-293, 22RV1, and NIH-3 T3 cells were
obtained from ATCC but not authenticated by the authors.hERG Assay
TP-3654 was tested for effect on hERG potassium channels by
automated patch clamp method (QPatchHTX, Sophion, Stockholm,
Sweden) at WuXi AppTec (Shanghai, China). CHO cells stably
expressing hERG potassium channels from Aviva Biosciences
(San Diego, CA) were tested with TP-3654 at six concentrations,
three-fold dilution starting at 30 μMwith a final DMSO concentration
of 0.15%, and compared to vehicle (negative) control and Amitriptyline
(WuXi AppTec, Shanghai, China) (positive) controls. Percentage of
control (vehicle) values was calculated in duplicate for each
concentration of drug, and curve-fitting and IC50 calculations were
performed by QPatch Assay Software (Sophion, Stockholm, Sweden).
Statistical Analysis and IC50/effective concentration 50%
(EC50) Determination
Statistical analyses were performed by parametric analysis of
variance test. IC50 and EC50 values were determined using GraphPad
Prism software (La Jolla, CA).
Small hairpin RNA (shRNA) Transduction
UM-UC-3 cells (2.5 × 105) were seeded in a six-well plate in complete
RPMI 1640 media and allowed to adhere overnight at 37°C in 5%CO2.
Cells were transduced with 8 μg/ml polybrene (Sigma-Aldrich, St. Louis,
MI) and lentiviral particles at a multiplicity of infection of 50 based on
titer values predetermined by Sigma-Aldrich using a p24 ELISA for each
batch of shRNA. Following overnight transduction, viral-particle–
containing media were removed and replaced with fresh complete
media, and cells were cultured for an additional 48 hours at 37°C in 5%
CO2. Cells were trypsinized, and fractions of the transduced cells were
collected for colony formation growth assays, whereas the remaining cells
were collected for RNA and protein isolation.
Reverse Transcription–Polymerase Chain Reaction
RNA from 0.5 × 106 cells was isolated on a QIAcube (Qiagen, Santa
Clarita, CA) using the protocol for purification of total RNA from
animal cells (QIAshredder homogenization and on-column DNasedigest) and quantified using a NanoDrop 8000 spectrophotometer
(Thermo Electron, West Palm Beach, FL). Total RNA (1 μg) was
converted to cDNA in a 20-μl reaction using the iScript cDNA synthesis
kit (Bio-Rad Laboratories, Hercules, CA) by incubating the reaction
components for 5 minutes at 25°C and 30 minutes at 42°C, followed by
5 minutes at 85°C. The cDNA reaction (2 μl) was used in a 20-μl
polymerase chain reaction (PCR) multiplex reaction using 1X FAM-
labeled PIM-1, VIC-labeled actin TaqMan primer sets, and the TaqMan
Gene Expression Master Mix from Life Technologies (Carlsbad, CA) on
an iQ5Real-Time PCRmachine (Bio-Rad Laboratories). An eight-point,
half-log standard curve was generated for PIM-1 and actinmessages using
RNA from untreated cells. A linear trend line (with an R2 value N0.99)
was generated by plotting log concentrations of standard versus Ct values
generated from the real-time PCR reactions. Relative message levels from
shRNA-treated samples were calculated on the basis of the standard curve,
normalized to actin, and compared to the nontarget shRNA control.Colony Formation Assay
For shRNA growth experiments, 500 UM-UC-3 cells were seeded in
a 12-well plate 48 hours posttransduction and cultured for 8 to 10 days
at 37°C in 5% CO2. Cells were fixed with 4% paraformaldehyde in
phosphate-buffered saline (PBS), washed twice with PBS, and stained
with a crystal violet solution (1% crystal violet, 10% ethanol in water).
Stained cells were washed thrice with water and imaged after drying on a
GelCount colony counter (Oxford Optronix Ltd, Oxford, United
Kingdom). Total staining intensity per well was determined by lysis of
cells with 200 μl of Triton X-100 lysis buffer [1% Triton X-100,
50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 1 mM EDTA].
Lysates (100 μl) from each well were transferred to a clear 96-well plate,
and absorbance at 560 nm was determined on an EnVision microplate
reader PerkinElmer (Waltham, MA). IC50 values were determined
using GraphPad Prism software. For compound-treated T24 and UM-
UC-3, cells were seeded and stained as above but were incubated with
various concentrations of TP-3654 or DMSO 1 day after seeding.
Cell Lysis and Western Blots
In all applications, cells were washed with cold PBS and then
treated with cell lysis solution (Cell Signaling Technology,
Danvers, MA). Lysates were centrifuged at 14,000g at 4°C
according to the protocol. Protein levels were then measured and
normalized using the BCA Protein Assay (Thermo Fisher Scientific,
Rockford, IL). Normalized amounts of lysate were then run on
precast gels according to the manufacturer protocol, using MOPS
running solution (Life Technologies). Gels were transferred using
the iBlot system (Life Technologies) and then blocked for 1 hour in
a 5% nonfat dry milk TBS-Tween (TBST) solution. Blots were
treated with specified antibodies (all provided by Cell Signaling
Technology) diluted 1:1000 in 5% BSA-TBST solution separately
on a blot shaker overnight at 4°C. Blots were rinsed three times for
5 minutes each after antibody treatments, according to the
protocol. The blots were treated with rabbit secondary antibody
solutions (Cell Signaling Technology) for 1 hour at room
temperature diluted 1:1000 in a 5% nonfat dry milk TBST
solution. As with the primary antibodies, the blots were rinsed three
times for 5 minutes each before imaging with an enhanced
chemiluminescence kit. The blots were stripped and then re-
treated overnight with actin when used as a loading control. As
explained previously, the blots were treated in antibody solution
diluted 1:1000 in 5% BSA-TBST solution overnight. Blots were
10-10 10-9 10-8 10-7 10-6 10-5 10-4
-25
0
25
50
75
100
125
%
 C
on
tro
l
TP-3654 [M]
C
A B
Figure 1. Structure and analysis of TP-3654. (A) TP-3654 compound structure is shown. (B) Selectivity analysis of TP-3654. IC50 values are
shown for the most potently inhibited kinases. PIM kinase values are Ki values, which were comparable to the IC50 determinations. (C) The
PIM-1–specific cellular EC50 of TP-3654was determined in a phospho-BAD (S112) Surefire (PerkinElmer,Waltham,MA) assay using HEK-293
cells transfected with BAD and PIM-1. The graph represents data from a single experiment, where the EC50 values from four independent
experiments (average = 67 nM) were determined using GraphPad Prism software.
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described previously.
TP-3654 Treatment
UM-UC-3 bladder cancer cells were seeded in six-well plates at a
concentration 2.5 × 105 cells per well, allowed to grow for 12 hours,
and then treated with 3, 1, 0.3, and 0.03 μM TP-3654 with 0.1%
DMSO (vehicle)–treated cells as a negative control. Cells were
incubated with the drug for 12 hours and then lysed as described above.
Urothelial Carcinoma Pathology Cases
One hundred thirty-seven cases of urothelial carcinoma were
included in this retrospective study of surgical biopsy and resection
specimens from the Department of Pathology, University of Utah
(Salt Lake City, UT) (retrieved from 2008 to 2011). Tissue was stained
with commercially available antibodies against PIM-1, PIM-2, and
PIM-3. Cases were classified into three groups according to World
Health Organization criteria [invasive high-grade urothelial carcinoma
(n = 84), noninvasive high-grade urothelial carcinoma/carcinoma in situ
(n = 32), and noninvasive low-grade urothelial carcinoma (n = 21)].
Individual cases were reviewed by two of the authors (D.J.A./T.L.) andTable 1. Biochemical *, FLT3 †, and hERG ‡ Potency Comparison of TP-3654 and SGI-1776
Compound PIM-1 Ki
(nM)
PIM-2 Ki
(nM)
PIM-3 Ki
(nM)
FLT3 IC50
(nM)
hERG IC50
(μM)
Molecular Weight
SGI-1776 12 980 20 3 b1 405
TP-3654 5 239 42 279 N30 419
* Ki determined by Reaction Biology as described in the Materials and Methods section.
† FLT3 IC50 determined by Reaction Biology as described in the Materials and Methods section.
‡ hERG IC50 determined byWuXi AppTec using the QPatch
HTX functional hERG assay described in the
Materials and Methods section.given a score (0-4) based on a percentage of cells demonstrating positive
cytoplasmic and/or nuclear staining for each antibody (b5% = 0; 5%-
25% = 1; 26%-50% = 2; 51%-75% = 3; N75% = 4). A score of 2 or
greater was considered positive staining.
Tumor Xenograft Studies
Male and female Nu/Nu mice were purchased from Harlan
Sprague Dawley (Indianapolis, IN). Female Nu/Nu mice were used
for all xenograft evaluations with the exception of the PC-3 (prostate
adenocarcinoma) xenografts where male Nu/Nu mice were used. Cell
lines were expanded in vitro in complete media and if adherent were
harvested by trypsin-EDTA, centrifuged, and resuspended in PBS 1:1
with Matrigel (BD Biosciences, San Jose, CA). Cells were inoculated
subcutaneously in the right hind flank of mice. When tumors reached
100 to 200 mm3 by caliper measurement, mice were randomized,
and oral dosing of TP-3654 or vehicle control began and continued
every day for 5 days (quaque die [QD] × 5) with 2 days off for 18 to
21 days. Tumor volumes and body weights were determined twice a
week, and tumor weights were measured at the completion of the
translational xenograft studies.
Pharmacokinetic Study
Female Sprague Dawley® (SD) rats with jugular vein catheters were
acquired from Charles River Laboratories (Wilmington, MA) and
allowed to acclimate at Tolero's laboratory facility for 3 days. Rats
were fasted (no food but with water) for 12 hours before the dosing.
Animals (three per group) were dosed with TP-3654 by oral gavage at
a dose of 40 mg/kg in a volume of 400 μl per 10 g of body weight.
TP-3654 was formulated in a solution of 10% polysorbate 20.
Animals dosed IV were heated under a heat lamp before dosing to
allow vasodilatation and visualization of the tail vein. These animals
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Figure 2. PIM-1 overexpression increases cellular pBAD levels, whereas TP-3654 decreases pBAD levels and PIM-1–driven xenografts.
(A) HEK293T cells were transfected with empty vector, PIM1, and PIM1 kinase dead (PIM1KD, K67M) alone or in combination with the
PIM substrate BAD using Effectene (Qiagen). Twenty-four hours posttransfection, cells were serum starved overnight and lysed for
Western blot detection of phospho-BAD (pBAD) at Ser112 using a Li-Cor Odyssey scanner (Lincoln, NE). (B) UM-UC3 cells were treated for
12 hours with 3, 1, 0.3, and 0.03 μM TP-3654. Separate, identical blots were treated with antibodies to measure levels of S112
phosphorylated BAD, total BAD, Th37/46 phosphorylated 4EBP1, and total 4EBP1. (C) Parental 22RV1 and 22RV1/PIM-1 cells (5 × 106)
were implanted per Nu/Nu mouse, with 10 mice per group. Mice were dosed by intraperitoneal injection with 25 mg/kg SGI-9481 or
vehicle, QD × 3 weeks, 5 days on 2 days off. Tumor measurements by caliper and body weights (data not shown) were obtained. P
values for caliper and body weights were *P= .023 and P= .0002, respectively. (D) Parental NIH-3 T3 and NIH-3 T3/PIM-2 cells (5 × 106)
were implanted per Nu/Nu mouse, with 10 mice per group. Mice were dosed by intraperitoneal injection with 25 mg/kg SGI-9481 or
vehicle, QD × 3 weeks, 5 days on 2 days off. Tumor measurements by caliper and body weights (data not shown) were obtained. P
values for caliper and body weights were *P = .002 and P = .0001, respectively.
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body weight. After injection, pressure was applied to the site for a few
seconds to stop bleeding from the injection. Immediately after each
animal received the full dose, time zero began, and blood was
collected at the following time points: 1, 5, 25, and 30 minutes and 1,
2, 4, 8, 24, and 48 hours postdose. At the designated time points, an
empty 1-ml syringe was used to clear the contents of the jugular vein
catheter that had been preloaded with heparin and discarded. A new
empty syringe was used to draw 200 μl of whole blood, and the blood
was immediately added to EDTA-coated tubes with the appropriate
labels. The tubes were gently shaken to ensure that the entire volume
of blood interacted with the EDTA to avoid clotting. The collected
blood was stored on ice until centrifugation and cryostorage of
plasma. A third syringe containing heparin was used to reload the
catheter to prevent clotting. After the blood was collected, it was
centrifuged at 5000 rpm for 5 minutes at 4°C. The plasma layer was
removed and stored at −80°C until extraction and analysis. These
steps were repeated until all time points in the study were collected
and properly stored. Plasma samples were extracted using standard
techniques and analyzed by liquid chromatography-mass spectrometry
to quantify TP-3654 concentrations. Pharmacokinetic parameters weredetermined using the PKSolver add-in program for Excel China
Pharmaceutical University (Nanjing, China).
Results
The second-generation PIM kinase inhibitor, TP-3654 (Figure 1A),
was discovered as a lead candidate on the basis of improved potency
against PIM-1 and PIM-2 and no appreciable hERG activity in vitro
compared to SGI-1776 (Table 1). TP-3654 was tested against a
panel of 340 kinases at 1 μM and inhibited 38 kinases by N50%
(Appendix A). IC50 determinations of 38 protein kinases and 4
additional lipid kinases (PI3K family) revealed 22 kinases with IC50
values below 300 nM (Figure 1B). TP-3654 displays at least 10-fold or
greater selectivity for PIM-1 compared to any other kinase tested. One
notable kinase family inhibited by TP-3654 was PI3K (γ, δ, and α),
whereas selectivity against FLT3 was reduced by nearly 100-fold relative
to SGI-1776 (Table 1).
The cellular potency of TP-3654 was determined by measuring its
effect on baseline phosphorylation of BAD, a known substrate of
PIM, on serine 112 by overexpression of PIM-1 and BAD in HEK-
293 cells. Overexpression of the catalytically inactive mutant PIM-1
(K67M) did not increase phosphorylation of BAD compared to BAD
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Figure 3. Validation of PIM-1 in solid tumor models in vitro. (A) PIM-1 shRNAs or control shRNA (nontarget) was transfected into the UM-
UC-3 bladder carcinoma cell line, and PIM-1 mRNA, PIM-1 protein, and cell proliferation in a two dimensional colony formation assay were
evaluated. Cells were infected with lentiviral particles overnight, the media were changed, and the cells were collected at 48 hours
posttransduction for RNA or protein. A portion of cells were seeded in a six-well plate at 500 cells per well. Cells were fixed and stained
after 10 days of growth. Data for PIM-1 mRNA levels are the average (±SD) of two independent experiments, whereas Western blot and
colony formation assays are representative of three independent experiments. *P = .0028 and **P = .0002. (B) T24 (bladder) or (C) UM-
UC3 (bladder) cancer cell lines were seeded at (B) 300 or (C) 500 cells per well in a 12-well plate and treated the next day with titrated
concentrations of TP-3654 as indicated. Cells were grown for 10 or 6 days, respectively, stained for imaging, and lysed for quantitation by
absorbance at 560 nm. Data are representative of independent experiments evaluating TP-3654 using T24 and UM-UC3 cell lines, with an
average EC50 = 1.1 ± 0.4 μM (n= 4) and 2.2 ± 0.2 μM (n= 2), respectively. Colorimetric quantification of cell growth was performed and
is provided as the graphs below the respective images with respective EC50 values.
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subtract BAD phosphorylation by cellular kinases other than PIM-1.
TP-3654 demonstrated potent PIM-1 specific cellular activity in the
PIM-1/BAD overexpression system with an average EC50 = 67 nM
(Figure 1C). In addition, TP-3654 treatment reduced levels of
phospho-BAD in vitro using the bladder cancer cell line UM-UC-3
(Figure 2B). To exclude the possibility that this phospho-BAD
decrease was due to off-target activity, we measured levels of phospho-
4EBP1 in parallel with phospho-BAD. We found no appreciable
difference in levels of phospho-4EBP1 in TP-3654–treated cells
(Figure 2B), providing further evidence that PIM inhibition was the
primary mechanism for the phospho-BAD decrease observed in TP-
3654–treated cells and not activity of the compound inhibiting AKT,
another known kinase that can phosphorylate BAD.
In an effort to demonstrate tumorigenicity of the PIM kinases and
to evaluate TP-3654 in PIM-driven tumor xenografts, PIM-1– and
PIM-2–overexpressing cell lines were developed. The prostate cancer
cell line 22RV1 engineered to overexpress PIM-1 as previously
described [48] was evaluated in vivo. A second model engineered tooverexpress PIM-2 was established using the NIH-3 T3 mouse
fibroblast cell line. PIM-1 overexpression in 22RV1 cells signifi-
cantly enhanced subcutaneous tumor growth compared to the
parental cell line when grown as mouse xenografts (22RV1 + vehicle
vs 22RV1/PIM-1 + vehicle), and the growth was significantly
reduced by administration of TP-3654 (22RV1/PIM-1 + vehicle vs
22RV1/PIM-1 + TP-3654) (Figure 2C). No significant changes in
body weight were observed in mice from any group. Similarly, PIM-2
overexpression in NIH-3 T3 cells significantly induced subcutane-
ous tumor growth compared to the parental cell line when grown in
mice (NIH-3 T3 + vehicle vs NIH-3 T3/PIM-2 + vehicle), and
the growth was significantly inhibited by TP-3654 (NIH-3 T3/
PIM-2 + vehicle vs NIH-3 T3/PIM-2 + TP-3654) (Figure 2D). No
significant changes in body weight were observed in any group.
The overexpression models extended the observed anti-PIM activity
of TP-3654 in vitro to antitumor activity in vivo. Translational models
with more clinical relevance were explored for PIM dependency using
shRNA knockdown. The UM-UC-3 urinary epithelial bladder
carcinoma cell line was used to verify and validate dependency on
A B
C D
Figure 4. PIM2 kinase expression in urothelial carcinoma cases. (A) Immunohistochemical stained sections of noninvasive low-grade
papillary urothelial carcinoma (×200) are shown. (B) Noninvasive high-grade urothelial carcinoma (400×) is shown. (C) Invasive high-grade
urothelial carcinoma (×400) is shown. (D) No expression in an invasive high-grade urothelial carcinoma (×400) is shown.
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reduced using two independent shRNAs targeting PIM-1 compared to
the nontarget shRNA control (Figure 3A). Furthermore, PIM-1 protein
was reduced using PIM-1 shRNA compared to nontarget shRNA, and
colony growth in soft agar was markedly reduced with PIM-1
knockdown (Figure 3A), comparable to a previous report in the
literature [17]. Additionally, TP-3654 reduced colony growth of T24
and UM-UC3 cells (Figure 3, B and C, respectively), confirming the
PIM-1–dependent growth for both cell lines.
Because PIM kinases have been implicated in a number of cancers
including hematological and prostate cancers [16,40,41,49–53], we
evaluated PIM expression in low, high, noninvasive, and invasive
bladder cancer cases. Evaluation of PIM expression by immunohis-
tochemistry revealed a significant number of cases in which PIM was
expressed in greater than 25% of the neoplastic cell population
(Figure 4 and Table 2). Low-grade noninvasive tumors demonstrated
the highest percentage of cases expressing PIM-1 (43%) and PIM-3
(52%), whereas invasive high-grade lesions demonstrated the lowest
percentage of PIM-1 (12%) and PIM-3 (13%) staining. PIM-2 was
overexpressed in the majority of noninvasive high-grade cases (63%)
and in a significant minority of invasive high-grade cases (38%) and
noninvasive low-grade cases (33%).Table 2. PIM Kinase Expression in Urothelial Carcinoma
PIM-1 PIM-2 PIM-3
Type Total N No. (Positive) % No. (Positive) % No. (Positive) %
NILG 21 9 43% 7 33% 11 52%
NIHG 32 12 38% 20 63% 9 28%
IHG 84 10 12% 32 38% 11 13%
Number of cases staining positive (scores 2-4) or negative (scores 0-1) in noninvasive low-grade
urothelial carcinoma (NILG), noninvasive high-grade urothelial carcinoma (NIHG), and invasive
high-grade urothelial carcinoma (IHG).We next tested whether TP-3654 could inhibit the growth of
established mouse xenograft tumors using the UM-UC-3 and PC-3 solid
tumor cell lines that were tested in vitro. Oral dosing of 200 mg/kg TP-
3654 significantly reduced both UM-UC-3 and PC-3 tumor growth
measured by volume (caliper) and by final tumor weight, with no
significant changes in body weight or gross adverse toxicity (Figure 5).
Previous studies showedthatSGI-1776exhibited favorablepharmacokinetic
properties [42], sowedetermined ifTP-3654 retainedor possibly improved on
the pharmacokinetic parameters of SGI-1776. A pharmacokinetic study in
female rats was carried out as described in theMaterials andMethods section.
Rats were orally dosed with TP-3654 formulated in 10% polysorbate 20
and compared to IV injected control (Figure 6). This formulation showed
favorable oral bioavailability at 39%. Using this formulation, theTmax for
TP-3654 was 1 hour, with a half-life of 4.1 hours (Figure 6).Discussion
PIM kinases play central roles in tumor cell survival and protection
from apoptosis, implicating this family of kinases as valid therapeutic targets
[16–19]. To date, numerous inhibitors of PIM kinases that exhibit growth
suppressive activity in tumor cell line models in vitro and in vivo have been
generated [9,11,14,33,54–57]. Previous PIM kinase inhibitors demon-
strated antitumor activity in xenograft models of FLT3-ITDmutant AML
and renal cell carcinoma [40,50–53,58]. A recently developed pan-PIM
inhibitor has shown promising activity as single agent and in combination
with cytarabine in AML xenograft models [59]. Other studies with the
same agent have shown promise in multiple myeloma [21]. We have
developed a novel small-molecule PIM kinase inhibitor that reduces the
growth of solid tumor xenografts where the tumorigenicity is mediated by
overexpression of PIM-1 or PIM-2, as well as human bladder carcinoma
tumors. Compared to first-generation inhibitor, TP-3654 shows no
appreciable hERG activity, suggesting that it would not carry the same
cardiotoxic side effects that terminated the phase I trial of SGI-1776.
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Figure 5. TP-3654 inhibits the growth of established solid tumor xenografts. (A) UM-UC-3 bladder carcinoma cells (5 × 106) were
implanted per Nu/Nu mouse, with 12 mice per group. Mice were dosed with TP-3654 orally at 200 mg/kg QD, 3 weeks, 5 days on 2 days
off or with vehicle. Caliper measurements (left panel) and tumor weights at the end of the study (middle panel) are shown. No significant
change in body weights was observed (right panel). *P = .0028 and **P = .02. (B) PC-3 prostate adenocarcinoma cells (7.5 × 106) were
implanted per male Nu/Nu mouse, with 12 mice per group. Mice were dosed with TP-3654 orally at 200 mg/kg QD, 3 weeks, 5 days on
2 days off or with vehicle. Caliper measurements (left panel) and tumor weights at the end of the study (middle panel) are shown. No
significant change in body weights was observed (right panel). *P = .007 and **P = .0002.
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characterized in AML and prostate cancers, we sought to further
evaluate the role of PIM kinases in bladder carcinomas. Previous workFigure 6. Oral pharmacokinetic data for TP-3654. Plasma levels of
TP-3654 (ng/ml) in female SD rats were determined using liquid
chromatography-mass spectrometry. Rats were dosed either by
IV injection at 2 mg/kg or orally at 40 mg/kg animal body weight. A
simple formulation consisting of 10% polysorbate 20 resulted in
the highest exposure (or area under the curve) and showed the
highest bioavailability when compared to the IV injected animals.evaluating bladder carcinoma indicated that PIM-1 was expressed in
more than 80% ofmalignant tissues compared with normal epithelia and
that expression was enhanced when comparing specimens derived
from patients with bladder cancer with invasive versus noninvasive
tumors [17]. Furthermore, it was shown that shRNA knockdown of
PIM-1 in bladder carcinoma cell lines reduced the growth of the cells
in vitro, indicating a prominent role for PIM-1 in bladder carcinoma
[17]. We evaluated TP-3654 in the bladder cancer model UM-UC-3
in vitro and showed that the compound induced similar effects as
PIM-1 shRNA-mediated knockdown (compare Figures 2B and 3A).
Examination of surgical resection cases of urothelial carcinoma
revealed PIM kinases expressed in a significant number of cases when
evaluated by immunohistochemistry. There was significant variation
across the different groups. Interestingly, PIM-1 and PIM-3 showed a
much higher percentage of cases with positive staining in low-grade
noninvasive carcinoma compared to invasive high-grade urothelial
carcinoma where only a small minority retained positive staining. PIM-
2 in comparison was expressed highest in a majority of noninvasive,
high-grade lesions and in more than one third of invasive lesions,
suggesting that PIM-2 expression remains important in more aggressive
clinical disease. These findings suggest that expression of PIM kinases
contributes to uncontrolled growth in low- and high-grade noninvasive
carcinoma and a smaller number of high-grade invasive tumors.
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terized by the mutation of growth factor signaling molecules, whereas
the high-grade, more aggressive tumors contain significant loss of tumor
suppressor genes [60]. PIM kinase expression is regulated by cytokine
signaling, and PIM kinases act as downstream effectors of transcription
factors such as c-MYC [61]. PIM kinases also act to inhibit apoptosis by
interacting with B cell lymphoma 2 family members such as BAD.
Because PIM kinases act as downstream effectors and inhibitors of
apoptosis, it is reasonable to expect that they could be expressed in any
type of urothelial carcinoma. This hypothesis is consistent with our
observation of PIM-1, PIM-2, and PIM- 3 expression in high- and low-
grade and invasive and noninvasive urothelial carcinomas. It is unclear
why PIM-1 and PIM-3 were predominantly expressed in low-grade,
noninvasive tumors, whereas PIM-2 showed higher expression in high-
grade tumors. Additional studies on the specific functions of PIM
kinases are needed to clarify their roles in the progression of urothelial
and other human carcinomas.
The rationale for targeting PIM kinases for the development of
cancer therapies includes their overexpression in a variety of
malignancies, correlation of high expression levels with poor patient
prognosis, their oncogenicity when overexpressed in cells, their role in
tumor cell survival as demonstrated by expression knockdown in
multiple cancer types, and the development of inhibitors with
preclinical activity that are emerging as clinical agents [37,45,59].
Together, these data support the long-standing effort to generate a
therapeutic platform from which to target this family of cell survival
kinases. Although the initial clinical evaluation of SGI-1776 was halted
due to a narrow therapeutic window, the significant potential for
therapeutic application of improved drug candidates remains. Given the
rapid pace of discovery, optimization, and development of new PIM
kinase inhibitors, one or more will likely gain momentum as a potential
treatment for both solid and hematologic malignancies, including
certain types of urothelial carcinomas.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.05.004.
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